Insider Transactions in Q1 2023 at Exact Sciences Corp (EXAS)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 03
2023
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
5,000
-30.45%
|
$325,000
$65.0 P/Share
|
|
Mar 01
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,000
-1.13%
|
$62,000
$62.0 P/Share
|
|
Mar 01
2023
|
Everett Cunningham Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,628
-13.78%
|
$224,936
$62.01 P/Share
|
|
Feb 28
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,233
-12.65%
|
$258,213
$61.12 P/Share
|
|
Feb 28
2023
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
2,225
-10.23%
|
$133,500
$60.55 P/Share
|
|
Feb 28
2023
|
D Scott Coward |
SELL
Open market or private sale
|
Direct |
4,153
-11.25%
|
$253,333
$61.12 P/Share
|
|
Feb 28
2023
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
6,832
-15.77%
|
$409,920
$60.55 P/Share
|
|
Feb 28
2023
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
10,416
-0.86%
|
$635,376
$61.12 P/Share
|
|
Feb 28
2023
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
1,932
-20.46%
|
$117,852
$61.12 P/Share
|
|
Feb 28
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
2,924
-3.19%
|
$178,364
$61.12 P/Share
|
|
Feb 27
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,137
+12.63%
|
-
|
|
Feb 27
2023
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
1,887
+7.43%
|
-
|
|
Feb 27
2023
|
Everett Cunningham Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,677
+22.57%
|
-
|
|
Feb 27
2023
|
D Scott Coward |
BUY
Exercise of conversion of derivative security
|
Direct |
9,194
+11.55%
|
-
|
|
Feb 27
2023
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
3,954
+14.53%
|
-
|
|
Feb 27
2023
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,492
+0.92%
|
-
|
|
Feb 27
2023
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
3,954
+29.52%
|
-
|
|
Feb 27
2023
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
6,311
+3.38%
|
-
|
|
Feb 22
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,033
-1.2%
|
$64,046
$62.72 P/Share
|
|
Feb 22
2023
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
398
-4.0%
|
$24,676
$62.72 P/Share
|
|
Feb 22
2023
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
4,764
-0.4%
|
$295,368
$62.72 P/Share
|
|
Feb 22
2023
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
2,710
-12.31%
|
$168,020
$62.72 P/Share
|
|
Feb 22
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,430
-5.55%
|
$88,660
$62.72 P/Share
|
|
Feb 22
2023
|
D Scott Coward |
SELL
Open market or private sale
|
Direct |
1,007
-3.5%
|
$62,434
$62.72 P/Share
|
|
Feb 22
2023
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
838
-13.25%
|
$51,956
$62.72 P/Share
|
|
Feb 21
2023
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,248
+2.54%
|
-
|
|
Feb 21
2023
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
865
+7.99%
|
-
|
|
Feb 21
2023
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,374
+0.86%
|
-
|
|
Feb 21
2023
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
5,897
+12.43%
|
-
|
|
Feb 21
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,112
+10.78%
|
-
|
|
Feb 21
2023
|
D Scott Coward |
BUY
Exercise of conversion of derivative security
|
Direct |
2,248
+7.25%
|
-
|
|
Feb 21
2023
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,729
+21.47%
|
-
|
|
Feb 16
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,076
-1.26%
|
$67,788
$63.91 P/Share
|
|
Feb 15
2023
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
400
-4.21%
|
$26,000
$65.59 P/Share
|
|
Feb 15
2023
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
954
-5.59%
|
$65,826
$69.59 P/Share
|
|
Feb 15
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
954
-1.11%
|
$62,010
$65.59 P/Share
|
|
Feb 15
2023
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
14,617
-1.21%
|
$950,105
$65.59 P/Share
|
|
Feb 15
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,866
-7.61%
|
$121,290
$65.59 P/Share
|
|
Feb 15
2023
|
D Scott Coward |
SELL
Open market or private sale
|
Direct |
1,821
-6.43%
|
$118,365
$65.59 P/Share
|
|
Feb 14
2023
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
883
+8.51%
|
-
|
|
Feb 14
2023
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
2,030
+10.63%
|
-
|
|
Feb 14
2023
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,030
+2.3%
|
-
|
|
Feb 14
2023
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,132
+2.52%
|
-
|
|
Feb 14
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,972
+13.94%
|
-
|
|
Feb 14
2023
|
D Scott Coward |
BUY
Exercise of conversion of derivative security
|
Direct |
3,972
+12.3%
|
-
|
|
Feb 13
2023
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
4,527
-0.38%
|
$289,728
$64.55 P/Share
|
|
Feb 13
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,158
-5.33%
|
$74,112
$64.55 P/Share
|
|
Feb 10
2023
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,705
+0.82%
|
-
|
|
Feb 10
2023
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,579
+10.62%
|
-
|
|
Feb 01
2023
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,000
-1.18%
|
$67,000
$67.93 P/Share
|